Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - GenMark Diagnostics, Inc. | d8k.htm |
EXHIBIT 99.1
GenMark Diagnostics Reports
First Quarter 2011 Results
Revenues Grow 91% and Placements Increase by 20 to 102
CARLSBAD, Calif., May 9, 2011 (BUSINESS WIRE) — GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported financial results for the first quarter ended March 31, 2011.
Revenues and net loss for the three months ended March 31, 2011 were $764,000 and $0.56 per share compared with $399,000 and $0.68 per share during the first quarter of 2010. The 91% increase in revenue reflects an increase in the number of systems in the field, growth in the Company’s test menu and increased volumes of tests sold. Reagent revenues grew 114% year over year to $621,000, while instrument and other revenues grew 31%. The Company placed 20 analyzers during the quarter.
Gross margin was a loss of $879,000, reflecting the manufacturing overhead spend due to duplicative manufacturing facilities. During the quarter the Company ceased manufacturing in its Pasadena, CA facility and is consolidating manufacturing in its Carlsbad, CA facility. The Company expects that the transition will be completed during the second quarter of 2011.
Operating expenses increased $1.1 million to $5.8 million during the first quarter of 2011, driven primarily by research and development spending as well as additional quality and regulatory costs associated with certifying the Carlsbad, CA manufacturing facility. Other operating expenses were approximately unchanged from the same quarter in 2010.
The Company ended the first quarter with $17.1 million in cash compared with $18.3 million at year-end, having used $3.1 million in cash flow from operations during the first quarter of 2011 compared with $5.0 million in the first quarter of 2010. The Company collected a $1.6 million Therapeutic Tax Credit in the period, which had been recorded in other assets at year end. Depreciation and amortization was $289,000 and capital expenditures were $346,000. The Company drew $2 million on its loan facility.
“The first quarter of 2011 marks a milestone in the evolution of GenMark,” commented Christopher Gleeson, GenMark’s Chairman and CEO. “With the addition of CEO, Hany Massarany and CFO, Paul Ross, we now have a complete and highly capable management team in place. In addition, our manufacturing is now consolidated into one facility, and customer interest in our products is growing at an accelerated pace. As such, our operational focus is on execution, as we manage the high level of growth we expect to experience in the near and long term,” Gleeson further stated,
INVESTOR CONFERENCE CALL
1
GenMark will hold a conference call to discuss first quarter 2011 results and the outlook for the current year at 4:00PM EST today. The conference call and webcast can be accessed live through the company’s website under the Investor Relations section. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number “64581484” approximately five minutes prior to the start time.
ABOUT GENMARK
GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark’s XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed five diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.
SAFE HARBOR STATEMENT
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding continued growth in sales of our diagnostic tests, the expansion of our diagnostic test menu, and the continued development of our technology, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
SOURCE: GenMark Diagnostics, Inc.
GenMark Diagnostics, Inc.
Paul Ross
Chief Financial Officer
760-448-4318
2
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| As of March 31, 2011 |
As of December 31, 2010 |
|||||||
| Current assets |
||||||||
| Cash and cash equivalents |
$ | 17,054,095 | $ | 18,329,079 | ||||
| Accounts receivable, net |
762,272 | 677,648 | ||||||
| Inventories, net |
871,033 | 896,809 | ||||||
| Other current assets |
382,194 | 2,193,160 | ||||||
| Total current assets |
19,069,594 | 22,096,696 | ||||||
| Property and equipment, net |
2,762,362 | 2,702,478 | ||||||
| Intangible assets, net |
68,042 | 70,980 | ||||||
| Other long-term assets |
55,355 | 55,355 | ||||||
| Total assets |
$ | 21,955,353 | $ | 24,925,509 | ||||
| Current liabilities |
||||||||
| Accounts payable |
$ | 1,651,985 | $ | 823,242 | ||||
| Accrued compensation |
1,019,545 | 1,171,989 | ||||||
| Other current liabilities |
1,761,011 | 1,249,928 | ||||||
| Total current liabilities |
4,432,541 | 3,245,159 | ||||||
| Long-term liabilities |
||||||||
| Loan Payable |
2,000,000 | — | ||||||
| Other non-current liabilities |
622,644 | 612,932 | ||||||
| Total liabilities |
$ | 7,055,185 | $ | 3,858,091 | ||||
| Stockholders’ equity |
||||||||
| Common stock, $.0001 par value; 100,000,000 authorized; 11,738,233 and 11,723,512 issued and outstanding as of March 31, 2011 and December 31, 2010, respectively |
1,172 | 1,172 | ||||||
| Preferred stock, $0.0001 par value; 5,000,000 authorized, none issued |
— | — | ||||||
| Additional paid-in capital |
166,483,672 | 166,009,084 | ||||||
| Accumulated deficit |
(151,134,719 | ) | (144,492,881 | ) | ||||
| Accumulated other comprehensive loss |
(449,957 | ) | (449,957 | ) | ||||
| Total stockholders’ equity |
14,900,168 | 21,067,418 | ||||||
| Total liabilities and stockholders’ equity |
$ | 21,955,353 | $ | 24,925,509 | ||||
3
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended March 31, |
||||||||
| 2011 | 2010 | |||||||
| Product Revenue |
$ | 692,739 | $ | 384,249 | ||||
| License and other revenue |
71,664 | 15,015 | ||||||
| Total revenue |
764,403 | 399,264 | ||||||
| Cost of sales |
1,643,456 | 567,396 | ||||||
| Gross loss |
(879,053 | ) | (168,132 | ) | ||||
| Operating expenses |
||||||||
| Sales and marketing |
1,130,389 | 1,058,285 | ||||||
| General and administrative |
2,111,336 | 2,167,264 | ||||||
| Research and development |
2,528,252 | 1,453,759 | ||||||
| Total operating expenses |
5,769,977 | 4,679,308 | ||||||
| Loss from operations |
(6,649,030 | ) | (4,847,440 | ) | ||||
| Other income |
||||||||
| Foreign exchange gain (loss) |
11,899 | (1,110 | ) | |||||
| Interest income |
6,258 | 4,654 | ||||||
| Total other income |
18,157 | 3,544 | ||||||
| Loss before income taxes |
(6,630,873 | ) | (4,843,896 | ) | ||||
| Provision for income taxes |
(10,968 | ) | (5,049 | ) | ||||
| Net loss |
$ | (6,641,841 | ) | $ | (4,848,945 | ) | ||
| Net loss per share, basic and diluted |
$ | (0.56 | ) | $ | (0.68 | ) | ||
| Weighted average number of shares outstanding |
11,771,014 | 7,113,922 | ||||||
| Condensed consolidated statements of comprehensive loss three and three months ended March 31, 2011 and 2010 |
||||||||
| Net loss |
$ | (6,641,841 | ) | $ | (4,848,945 | ) | ||
| Foreign currency translation adjustment |
— | (34,647 | ) | |||||
| Comprehensive loss |
$ | (6,641,841 | ) | $ | (4,883,592 | ) | ||
4
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months
Ended March 31, |
||||||||
| 2011 | 2010 | |||||||
| Cash flows from operating activities: |
||||||||
| Net loss |
$ | (6,641,841 | ) | $ | (4,848,945 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Depreciation and amortization |
288,771 | 318,369 | ||||||
| Change in allowance for doubtful accounts, net of write-offs |
(47,785 | ) | — | |||||
| Change in allowance for excess and obsolete inventory |
(546 | ) | — | |||||
| Share-based compensation |
474,588 | 347,530 | ||||||
| Changes in operating assets and liabilities: |
||||||||
| Trade accounts receivable |
(36,839 | ) | (71,316 | ) | ||||
| Inventories |
26,322 | (65,138 | ) | |||||
| Other current assets |
1,810,966 | (469,561 | ) | |||||
| Accounts payable |
667,559 | (316,564 | ) | |||||
| Accrued compensation |
(152,444 | ) | 279,184 | |||||
| Accrued and other liabilities |
520,798 | (155,724 | ) | |||||
| Net cash used in operating activities |
(3,090,451 | ) | (4,982,165 | ) | ||||
| Investing activities: |
||||||||
| Purchases of property and equipment |
(184,533 | ) | (137,440 | ) | ||||
| Net cash used in investing activities |
(184,533 | ) | (137,440 | ) | ||||
| Financing activities: |
||||||||
| Proceeds from issuance of ordinary shares and common stock |
||||||||
| Proceeds of loan payable |
2,000,000 | — | ||||||
| Proceeds from stock option exercises |
— | 4,734 | ||||||
| Net cash provided by financing activities |
2,000,000 | 4,734 | ||||||
| Effect of foreign exchange rate changes |
— | (46,935 | ) | |||||
| Net decrease in cash and cash equivalents |
(1,274,984 | ) | (5,114,871 | ) | ||||
| Cash and cash equivalents at beginning of period |
18,329,079 | 16,482,818 | ||||||
| Cash and cash equivalents at end of period |
$ | 17,054,095 | $ | 11,321,012 | ||||
| Noncash investing and financing activities: |
||||||||
| Reclassification of deposits on systems in other current assets |
— | $ | 285,284 | |||||
| IPO costs incurred but not paid |
— | 1,537,192 | ||||||
| Property and equipment costs incurred but not paid |
$ | 161,184 | — | |||||
5